Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
European Journal of Gynaecological Oncology
|
May 23, 2012
The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials
J Vitfell-Pedersen, T A Yap, V Moreno, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 27, 2016
Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer
A Weller, M E R O'Brien, M Ahmed, et al.
British Journal of Cancer
|
July 2, 2014
Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail
M Ong, S Carreira, J Goodall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 22, 2011
A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies
H-T Arkenau, R Plummer, L R Molife, et al.
British Journal of Cancer
|
November 12, 2015
Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials
E Geuna, D Roda, S Rafii, et al.
British Journal of Cancer
|
January 13, 2016
Phase I trial outcomes in older patients with advanced solid tumours
K H Khan, T A Yap, A Ring, et al.
ESMO Open
|
August 30, 2024
PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors
T A Yap, A D Choudhury, E Hamilton, et al.
ESMO Open
|
November 12, 2025
Phase I trial of neratinib plus palbociclib in advanced cancers with HER family alterations
S A Piha-Paul, C Tseng, H T Tran, et al.
ESMO Open
|
February 5, 2025
Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations
S A Piha-Paul, C Tseng, H T Tran, et al.
ESMO Open
|
June 24, 2024
A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors
M A Gouda, J Shunyakova, A Naing, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
European Journal of Gynaecological Oncology
|
May 23, 2012
The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials
J Vitfell-Pedersen, T A Yap, V Moreno, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 27, 2016
Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer
A Weller, M E R O'Brien, M Ahmed, et al.
British Journal of Cancer
|
July 2, 2014
Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail
M Ong, S Carreira, J Goodall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 22, 2011
A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies
H-T Arkenau, R Plummer, L R Molife, et al.
British Journal of Cancer
|
November 12, 2015
Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials
E Geuna, D Roda, S Rafii, et al.
British Journal of Cancer
|
January 13, 2016
Phase I trial outcomes in older patients with advanced solid tumours
K H Khan, T A Yap, A Ring, et al.
ESMO Open
|
August 30, 2024
PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors
T A Yap, A D Choudhury, E Hamilton, et al.
ESMO Open
|
November 12, 2025
Phase I trial of neratinib plus palbociclib in advanced cancers with HER family alterations
S A Piha-Paul, C Tseng, H T Tran, et al.
ESMO Open
|
February 5, 2025
Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations
S A Piha-Paul, C Tseng, H T Tran, et al.
ESMO Open
|
June 24, 2024
A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors
M A Gouda, J Shunyakova, A Naing, et al.
Page
of 2